We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

108 hedge funds and large institutions have $377M invested in Aldeyra Therapeutics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

143% more capital invested

Capital invested by funds: $155M → $377M (+$222M)

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

52% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 21

29% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 24

10% more funds holding

Funds holding: 98108 (+10)

9.43% more ownership

Funds ownership: 57.71%67.13% (+9.4%)

16% less call options, than puts

Call options by funds: $4.16M | Put options by funds: $4.95M

Holders
108
Holders Change
+10
Holders Change %
+10.2%
% of All Funds
1.9%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
32
Increased
31
Reduced
24
Closed
21
Calls
$4.16M
Puts
$4.95M
Net Calls
-$793K
Net Calls Change
+$701K
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$103M +$27.8M +2,418,421 +38%
FLAM
2
First Light Asset Management
Minnesota
$31.2M +$30.2M +2,624,001 New
APM
3
Avidity Partners Management
Texas
$30.3M +$12.9M +1,117,000 +78%
State Street
4
State Street
Massachusetts
$28.8M +$27.7M +2,402,324 +11,605%
Vanguard Group
5
Vanguard Group
Pennsylvania
$24.4M +$5.03M +436,490 +27%
BlackRock
6
BlackRock
New York
$12.5M +$3.14M +273,024 +35%
Two Sigma Investments
7
Two Sigma Investments
New York
$10.5M +$2.48M +215,593 +32%
Two Sigma Advisers
8
Two Sigma Advisers
New York
$9.93M +$1.87M +162,100 +24%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$9.03M +$7.27M +631,306 +491%
WP
10
Woodline Partners
California
$8.68M +$8.41M +730,394 New
GTC
11
Ghost Tree Capital
New York
$7.72M
KCM
12
Knoll Capital Management
Florida
$6.76M
ACM
13
Altium Capital Management
New York
$6.51M +$6.31M +548,225 New
Millennium Management
14
Millennium Management
New York
$6.46M -$175K -15,232 -3%
PM
15
Prosight Management
Texas
$5.63M -$5.01M -435,042 -48%
Verition Fund Management
16
Verition Fund Management
Connecticut
$4.95M +$2.53M +219,963 +112%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$4.73M +$1.09M +94,932 +31%
JJIJ
18
Johnson & Johnson Innovation - JJDC
New Jersey
$4.69M -$2.3M -200,000 -34%
SCM
19
Silverarc Capital Management
Massachusetts
$3.82M +$3.71M +321,879 New
AAA
20
Affinity Asset Advisors
New York
$3.56M +$2.3M +200,000 +200%
Deutsche Bank
21
Deutsche Bank
Germany
$3.56M
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$3.27M +$78.3K +6,803 +3%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$3.22M +$2.24M +194,854 +257%
Citadel Advisors
24
Citadel Advisors
Florida
$3.06M -$12.3M -1,068,295 -81%
Citigroup
25
Citigroup
New York
$2.75M +$2.16M +187,298 +424%

ALDX Hedge Fund Activity: Q1 2021 in Review

108 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2021, worth a combined $377M — up 143% from $155M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new ALDX positions and 21 closed out — a net gain of 11 holders — while 31 added to existing stakes and 24 trimmed.

The largest buyer was First Light Asset Management, opening a new position worth an estimated $30.2M. The largest seller was Citadel Advisors, cutting an estimated $12.3M.

  • 108 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2021, up from 98 in Q4 2020.
  • Funds reported $377M of Aldeyra Therapeutics stock for Q1 2021, up 143% quarter-over-quarter.
  • 32 funds opened new Aldeyra Therapeutics positions in Q1 2021 and 21 closed out, a net change of +11 holders.
  • The largest Aldeyra Therapeutics buyer in Q1 2021 was First Light Asset Management, an estimated $30.2M added.
  • The largest Aldeyra Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $12.3M sold.

Based on aggregated 13F filings for Q1 2021.